secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001171843-24-006284
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Q3 net loss $40.2M; soquelitinib atopic dermatitis interim data due Dec 2024
--------------------------------------------------------------------------------

- Net loss of $40.2M for Q3 2024, including $32.8M non-cash warrant liability loss, vs $6.0M loss in Q3 2023.
- Cash, equivalents and marketable securities $41.7M at Sep 30, 2024; projected year-end cash $38-39M.
- October 2024 early warrant exercise raised $5.9M; approx. 15.4M warrants outstanding expiring June 2025.
- Soquelitinib Phase 1 atopic dermatitis trial second cohort (200mg QD) enrolling; interim data expected Dec 2024.
- Soquelitinib Phase 3 PTCL registrational trial enrolling at multiple sites; Orphan Drug and Fast Track granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/0001171843-24-006284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/f8k_111224.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer